Education
About Us
Working with TipRanks
Follow Us
AbbVie (DE:4AB)
XETRA:4AB
4AB Stock Chart & Stats
€196.00
-€0.44(-0.25%)
At close: 4:00 PM EST
€196.00
-€0.44(-0.25%)
Day’s Range― - ―
52-Week Range€147.60 - €207.00
Previous CloseN/A
Volume1.25K
Average Volume (3M)616.00
Market Cap
€339.28B
Enterprise Value€452.08B
Total Cash (Recent Filing)€5.26B
Total Debt (Recent Filing)€68.87B
Price to Earnings (P/E)96.8
Beta0.24
Next Earnings
Apr 24, 2026EPS Estimate
2.63Next Dividend Ex-DateN/A
Dividend Yield2.93%
Share Statistics
EPS (TTM)2.36
Shares Outstanding1,768,169,100
10 Day Avg. Volume390
30 Day Avg. Volume616
Financial Highlights & Ratios
PEG Ratio-116.18
Price to Book (P/B)-125.12
Price to Sales (P/S)6.69
P/FCF Ratio22.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€221.04Price Target Upside12.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)12.65
Revenue Forecast (FY)€58.30B
Bulls Say, Bears Say
Bulls Say
ABBV-295 Clinical SignalPhase I multiple‑ascending‑dose data for ABBV-295 indicate meaningful weight‑loss effects and a dose‑response trend, suggesting the candidate has molecular efficacy that could justify further development in the cardiometabolic market.
Commercial Execution And Guidance AlignmentStrong commercial performance from Skyrizi and Rinvoq, together with earnings and revenue beats that align with management guidance, reinforces expectations for sustained revenue growth and supports analyst optimism on valuation.
Skyrizi Subcutaneous InductionPivotal trial results show subcutaneous Skyrizi achieved clinical remission and endoscopic response in Crohn's disease with a favorable safety profile, supporting regulatory discussions and a potential label expansion to improve competitive convenience.
Bears Say
Competition In ImmunologyEmerging rival therapies and share gains by competitors increase pressure on Skyrizi and Rinvoq, creating uncertainty about the company's ability to maintain market share as additional entrants target immunology indications.
Investor Visibility And Execution RiskManagement's decision to stop providing mid‑cycle updates reduces interim visibility for investors and, combined with elevated market expectations, heightens the risk that weaker execution could trigger share‑price volatility.
Revenue Sustainability ConcernsEarnings outperformance driven largely by legacy products raises questions about the quality and sustainability of revenue growth if newer franchises fail to fully replace declining assets.
AbbVie News
4AB FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was €147.60 and its highest was €207.00 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is €339.28B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Apr 24, 2026 which is in 39 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Feb 04, 2026. The company reported €2.363 earnings per share for the quarter, beating the consensus estimate of €2.314 by €0.05.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of €1.467 which represents an annual dividend yield of 2.93%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 2.63.
How many shares outstanding does AbbVie have?
AbbVie has 1,768,169,100 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of €2.363 in its last earnings report, beating expectations of €2.314. Following the earnings report the stock price went down -7.477%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in DE:4AB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbbVie Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€221.04 (12.77% Upside)
€221.04 (12.77% Upside)
Blogger Sentiment
Bullish
DE:4AB Sentiment 86%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $14.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 86%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.32%
12-Months-Change
Fundamentals
Return on Equity
-361.58%
Trailing 12-Months
Asset Growth
-0.89%
Trailing 12-Months
Company Description
AbbVie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
4AB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed broad operational strength: record sales, multiple high‑growth franchises (notably SKYRIZI, RINVOQ, and neuroscience brands), significant R&D and BD investments, and an optimistic 2026 financial outlook (≈9.5% revenue growth, EPS guidance and margin expansion). Headwinds were clearly disclosed — substantial HUMIRA erosion, declines in IMBRUVICA and parts of aesthetics, acquired IPR&D charges compressing near‑term margins, and modest pricing pressure on key immunology assets — but management articulated clear mitigation levers (strong portfolio growth, new approvals, pipeline catalysts, BD additions, and a large free cash flow profile). Overall, positive execution and outlook outweigh the listed challenges.View all DE:4AB earnings summaries4AB Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
4AB Stock 12 Month Forecast
Average Price Target
€221.04
▲(12.77% Upside)
Technical Analysis
Options Prices
Currently, No data available
---